MCLEAN, VA / ACCESS Newswire / July 11, 2025 / Gladstone Land Corporation (Nasdaq:LAND) (“Gladstone Land” or the “Company”) announced that its board of directors has authorized a share repurchase program for up to $20,000,000 of the Company’s 6.00% Series B Cumulative Redeemable Preferred Stock (Nasdaq: LANDO) and up to $35,000,000 of the Company’s 6.00% Series C Cumulative Redeemable Preferred Stock (Nasdaq: LANDP) (together, the “Preferred Stock Repurchase Program”). The repurchases are intended to be implemented through open market transactions on U.S. exchanges or in privately negotiated transactions, in accordance with applicable securities laws, and any market purchases will be made during applicable trading window periods or pursuant to any applicable Rule 10b5-1 trading plans. The timing, prices, and sizes of repurchases will depend upon prevailing market prices, general economic and market conditions and other considerations. The board’s authorization of the Preferred Stock Repurchase Program expires July 10, 2026, and the Preferred Stock Repurchase Program may be suspended or discontinued at any time and does not obligate the Company to acquire any particular amount of preferred stock.
“After a thorough analysis and in consultation with our board of directors, we are announcing another share repurchase authorization as part of a capital allocation strategy that we believe is in the best interest of our shareholders and our business. We believe that the current market conditions provide an attractive buying opportunity for our preferred stock and that using capital to repurchase our preferred shares at appropriate prices represents a favorable strategic use of capital,” said David Gladstone, President of the Company.
About Gladstone Land Corporation:
Founded in 1997, Gladstone Land is a publicly traded real estate investment trust that acquires and owns farmland and farm-related properties located in major agricultural markets in the U.S. The Company currently owns 150 farms, comprised of approximately 103,000 acres in 15 different states and over 55,000 acre-feet of water assets in California. Gladstone Land’s farms are predominantly located in regions where its tenants are able to grow fresh produce annual row crops, such as berries and vegetables, which are generally planted and harvested annually. The Company also owns farms growing permanent crops, such as almonds, blueberries, figs, olives, pistachios, and wine grapes, which are generally planted every 20-plus years and harvested annually. Over 30% of the Company’s fresh produce acreage is either organic or in transition to become organic, and nearly 20% of its permanent crop acreage falls into this category. The Company may also acquire property related to farming, such as cooling facilities, processing buildings, packaging facilities, and distribution centers. Gladstone Land pays monthly distributions to its stockholders and has paid 149 consecutive monthly cash distributions on its common stock since its initial public offering in January 2013. The current per-share distribution on its common stock is $0.0467 per month, or $0.5604 per year. Additional information, including detailed information about each of the Company’s farms, can be found at www.GladstoneLand.com.
Owners or brokers who have farmland for sale in the U.S. should contact:
Lenders who are interested in providing Gladstone Land with long-term financing on farmland should contact Jay Beckhorn at (703) 587-5823 or Jay.Beckhorn@GladstoneCompanies.com.
For stockholder information on Gladstone Land, call (703) 287-5893. For Investor Relations inquiries related to any of the monthly dividend-paying Gladstone funds, please visit www.GladstoneCompanies.com.
CAUTION CONCERNING FORWARD-LOOKING STATEMENTS:
Certain statements in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements inherently involve certain risks and uncertainties, although they are based on the Company’s current plans that are believed to be reasonable as of the date of this press release. Factors that may cause actual results to differ materially from these forward-looking statements include, but are not limited to, the Company’s ability to procure financing for investments, downturns in the current economic environment, the performance of its tenants, the impact of competition on its efforts to renew existing leases or re-lease real property, and significant changes in interest rates. Additional factors that could cause actual results to differ materially from those stated or implied by its forward-looking statements are disclosed under the caption “Risk Factors” within the Company’s Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC on February 19, 2025, and certain other documents filed with the SEC from time to time. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
For further information: Gladstone Land, (703) 287-5893
SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier CB1-targeting drugs
MIAMI, FL / ACCESS Newswire / July 11, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) today announced new preclinical results from SKNY-1, an oral drug candidate for obesity and nicotine addiction currently under definitive agreement for acquisition. In a validated behavioral model used to measure Cannabinoid 1 receptor (CB1) related anxiety-like effects, SKNY-1 demonstrated clear reversal of anxiety-related behavior induced by a CB1 activator, setting it apart from earlier CB1-targeting drugs that were discontinued due to serious central nervous system (CNS) effects.
SKNY-1 is being developed as a potential oral treatment for obesity and addiction. It has previously been shown to achieve up to 30% weight loss, reverse high-calorie food and nicotine cravings, and preserve muscle mass in preclinical models. These new findings suggest that SKNY-1 may deliver these therapeutic effects without emotional or behavioral disruption, an important factor in long-term treatment adherence.
“These findings are a significant step forward,” said Erez Aminov, Chief Executive Officer of MIRA. “The ability to suppress appetite and cravings while reversing anxiety-like effects is critical. These results reinforce the differentiated approach behind SKNY-1 and its potential role as a novel oral treatment in large, underserved markets.”
About the Study
The study used the light-dark preference test in zebrafish-a validated behavioral model to assess anxiety-related responses. Zebrafish naturally prefer darker environments due to an innate fear of predators. However, when anxiety levels are elevated, they avoid the light even more strongly spending more time in the dark. Reduced dark preference (i.e., more time in the light) is interpreted as a calming effect.
Four groups were evaluated:
Control Group (No Drug): Fish showed balanced behavior between light and dark environments.
CP55,940 Group (CB1 Agonist): These animals spent significantly more time in the dark, confirming that CB1 activation increases anxiety at higher doses. Interestingly, at lower doses, CP55,940 produced a calming effect-reducing dark preference and encouraging exploration of the light area.
Rimonabant Group (CB1 Inverse Agonist): Fish treated with Rimonabant also showed increased dark-zone time and exhibited a greater increase in anxiety-like behavior than the CB1 agonist group, under both high and low doses of agonist-consistent with the known psychiatric effects that led to Rimonabant’s market withdrawal.
SKNY-1 Groups: In animals co-treated with CP55,940, SKNY-1 significantly reversed the anxiety-inducing effects of high-dose CP55,940 and enhanced the calming effects at low doses. In all conditions, SKNY-1 brought anxiety-like behavior back to control or better-than-control levels.
These results suggest SKNY-1 may help stabilize mood and stress-related behavior-a potential advantage in treating both metabolic and addictive disorders.
A New Approach to Endocannabinoid Modulation
SKNY-1 targets the endocannabinoid system (ECS)-a key regulator of hunger, emotion, reward, and addictive behavior-through a multi-pathway approach:
Biased CB1 antagonism blocks β-arrestin signaling (linked to cravings and compulsive behavior) while preserving G-protein signaling (important for emotional regulation).
CB2 partial agonism may reduce inflammation in the brain, which is increasingly recognized as a driver of anxiety, depression, and cognitive decline. By lowering neuroinflammation, SKNY-1 may help preserve emotional balance and support cognitive resilience.
Mild inhibition of MAO-B regulates dopamine, which plays a role in motivation and behavioral control.
No inhibition of MAO-A confirmed through in vitro screening-important because MAO-A inhibitors are associated with mood instability, drug interactions, and safety concerns.
This multi-target profile gives SKNY-1 a differentiated mechanism that may allow it to reduce cravings and weight while supporting emotional health-without the psychiatric side effects that limited earlier CB1 or MAO-based drugs.
“The ability to block cravings while preserving emotional balance is a key challenge in this field,” said Dr. Itzchak Angel, MIRA’s Chief Scientific Advisor. “SKNY-1 appears to meet that challenge head-on. The demonstration that its profile is significantly different than rimonabant in its interaction with CB1 agonists, reinforces the unique pharmacological profile of the drug.”
Market Opportunity
Obesity and addiction are among the most urgent and expensive public health challenges globally. In the U.S. alone, the economic burden of obesity and related chronic diseases is estimated at $1.7 trillion annually, equivalent to over 9% of the nation’s GDP (Milken Institute, 2023). Yet despite significant commercial investment, current therapies remain limited by efficacy gaps and tolerability challenges.
Current GLP‑1 therapies like semaglutide deliver weight loss but are injectables, often cause gastrointestinal side effects, and can result in loss of lean muscle mass. Smoking cessation therapies such as varenicline or bupropion offer modest long-term success and may carry psychiatric warnings that restrict their use in sensitive patient populations. Earlier CB1-targeting drugs, including rimonabant, were withdrawn due to severe mood disorders. Furthermore, broad MAO inhibition-especially MAO‑A-has long been associated with mood instability and dangerous food-drug interactions.
SKNY‑1 was developed to address those limitations directly. With oral administration, differentiated pharmacology, and potential dual efficacy in obesity and nicotine addiction, SKNY‑1 may offer a best-in-class profile. Its lack of MAO‑A inhibition, confirmed in vitro, further enhances its therapeutic promise.
Next Steps
MIRA is currently preparing for shareholder approval related to the proposed acquisition of SKNY Pharmaceuticals, Inc. Pending approval, the Company expects to initiate Investigational New Drug (IND)-enabling studies for SKNY-1 as a next step toward human clinical trials.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.
This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Clear Start Tax shows married couples how to avoid costly filing mistakes and save more when back taxes are involved.
IRVINE, CA / ACCESS Newswire / July 11, 2025 / Married taxpayers dealing with back taxes are often surprised to learn that filing separately to “protect” one spouse from IRS collections can actually lead to higher tax bills, lost credits, and fewer resolution options. According to Clear Start Tax, understanding the pros and cons of married filing jointly vs. separately is critical for couples hoping to resolve tax debt while preserving as much income as possible.
“Filing separately might feel safer when one spouse has IRS issues – but it usually ends up being more expensive,” said the Head of Client Solutions at Clear Start Tax. “In many cases, joint filing opens the door to relief programs, better deductions, and faster resolution.”
Why Filing Separately Can Backfire for Couples With Tax Debt
Some couples assume that filing separately shields one spouse’s income or refunds from being seized. While separate filing may delay IRS collection on a refund, it doesn’t always protect shared income or assets, especially in community property states. And in many cases, filing separately ultimately results in:
Higher overall tax liability
Loss of key deductions and credits (like the Earned Income Credit or Child Tax Credit)
Reduced access to Fresh Start benefits or less favorable Offer in Compromise terms
Longer resolution timelines and more paperwork
How Filing Together Could Be the Smartest Move for Tax Relief
Even when one spouse owes back taxes, joint filing can result in lower taxes and greater access to IRS relief programs. Clear Start Tax helps couples explore the advantages of working together, not separately.
Qualify for a lower combined tax rate
Maintain access to credits that reduce their liability
Negotiate as a unit for an Offer in Compromise or installment plans
Streamline the resolution process with one case file
For situations where only one spouse is responsible for the debt, programs like Innocent Spouse Relief or Injured Spouse Allocation may protect the non-liable spouse, without sacrificing the benefits of joint filing.
“The IRS gives couples a way to protect the innocent spouse while still getting the best outcome,” said the Head of Client Solutions. “We help clients understand their rights and design a strategy that keeps more money in their household.”
The Fresh Start Program Can Help Couples Settle Tax Debt Together
This IRS initiative allows struggling taxpayers – including married couples – to settle or restructure their tax debt based on what they can reasonably afford. Clear Start Tax walks couples through every step of the process.
Settlements for less than the full amount owed
Reduced penalties and halted interest
Affordable payment plans based on household income
By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.
Joint Returns Come With Risk – But Also With Options
While joint returns mean both spouses are legally responsible for the full tax bill, Clear Start Tax helps clients explore:
Partial-pay agreements
Spousal relief requests
Asset protection strategies
Custom IRS settlement negotiations
These strategies can balance legal responsibility while still maximizing the couple’s chances of saving money and moving forward.
About Clear Start Tax
Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.
TORONTO, ON / ACCESS Newswire / July 11, 2025 / Northern Superior Resources Inc. (“Northern Superior” or the “Company“) (TSXV:SUP)(OTCQB:NSUPF)(GR:D9M1) is pleased to announce that, in furtherance to a binding term sheet that was announced on June 16, 2025, it has entered into an asset purchase agreement with TomaGold Corporation for the acquisition of the Hazeur, Monster Lake East, and Monster Lake West Properties (the “Transaction“). Additional information regarding the Transaction and the properties is available in the initial announcement.
The Company anticipates the Transaction to close as early as next week.
About Northern Superior Resources Inc.
Northern Superior is a gold exploration company focused on the Chibougamau Camp in Québec, Canada. The Company has consolidated the largest land package in the region, with total land holdings currently exceeding 62,000 hectares. The main properties include Philibert, Lac Surprise, Chevrier, and Croteau. Northern Superior also owns 56% of ONGold Resources Ltd. (TSXV:ONAU) (OTCQX:ONGRF) which is advancing promising exploration assets in Northern Ontario and Manitoba, including the district-scale TPK Project and Monument Bay. Agnico Eagle Mines Limited owns 15% of ONGold Resources Ltd.
The Philibert Project is located 9 km from IAMGOLD Corporation’s Nelligan1 Gold project. Philibert hosts a maiden 43-101 inferred resource of 48.5 M tonnes at 1.10 g/t Au for 1,708,800 ounces Au and an indicated resource of 7.9 M tonnes at 1.10 g/t Au for 278,900 ounces Au.2 Northern Superior holds a majority stake of 75% in the Philibert Project, with the remaining 25% owned by SOQUEM, and retains an option to acquire the full 100% ownership of the project. Chevrier hosts an inferred mineral resource of 15.7 M tonnes at 1.29 g/t Au for 652,000 ounces Au (underground and open pit) and an indicated mineral resource of 6.4 M tonnes at 1.26 g/t Au for 260,000 ounces Au.3 Croteau hosts an inferred mineral resource of 11.6 M tonnes at 1.7 g/t Au for 640,000 ounces Au.4 Lac Surprise hosts the Falcon Zone Discovery, interpreted to be the western strike extension of IAMGOLD Corporation’s Nelligan Gold project.
Northern Superior is a reporting issuer in British Columbia, Alberta, Ontario and Québec, and trades on the TSX-V under the symbol SUP and the OTCQB Venture Market under the symbol NSUPF. For further information, please refer to the Company’s website at www.nsuperior.com or the Company’s profile on SEDAR+ at www.sedarplus.ca.
Qualified Person (“QP”)
The technical content and drilling results contained in this news release have been prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101“) and have been reviewed and approved by Ms. Melanie Pichon, P.Geo., Senior Geologist for Northern Superior. Ms. Pichon is a QP under the NI 43-101 and is not considered independent.
Northern Superior Resources Inc. on Behalf of the Board of Directors
Simon Marcotte, CFA, President and Chief Executive Officer
Contact Information Katrina Damouni Director – Corporate Development Tel: +44 7795 128583 (Mobile/WhatsApp) info@nsuperior.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections and interpretations as at the date of this news release. The information in this news release about the Transaction, the timing of the Transaction and any other information herein that is not a historical fact may be “forward-looking information”. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “interpreted”, “management’s view”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward- looking information and are intended to identify forward-looking information. This forward-looking information is based on reasonable assumptions and estimates of management of Northern Superior, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither party nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. Neither party undertakes, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law.
1 “lAMGOLD Announces Significant Increase in Nelligan Ounces & Update of Global Mineral Reserves and Resources”;
IAMGOLD reports increase in mineral reserves and resources at existing assets, with increase in resources at Gosselin; IAMGOLD Corporation News Release dated February 15, 2024, October 23, 2024, and February 20, 2025. Note that the technical and scientific information disclosed from neighboring properties does not apply to any other properties of the area.
2 Independent Technical Report MINERAL RESOURCES ESTIMATION OF THE PHILIBERT PROJECT Québec, Canada. September 22, 2023. Prepared in accordance with NI 43-101 by Goldminds Geoservice Inc. to Northern Superior Resources. Philibert hosts a maiden 43-101 inferred resource of 48.5 Mt at 1.10 g/t Au for 1,708,800 ounces Au and an indicated resource of 7.9 Mt tonnes at 1.10 g/t Au for 278,900 ounces Au Note that the technical and scientific information disclosed from neighboring properties does not apply to any other properties of the area.
3 NI 43-101 Technical Report Mineral Resource Estimation for the Chevrier Main Deposit, Chevrier Project Chibougamau, Quebec, Canada, October 20, 2021, Prepared in accordance with NI 43-101 by Lions Gate Geological Consulting Inc. IOS Services Géoscientifiques Inc. for Northern Superior. Chevrier hosts an inferred mineral resource of 15.7 Mt at 1.29 g/t Au for 652,000 ounces Au (underground and open pit) and an indicated mineral resource of 6.4 Mt at 1.26 g/t Au for 260,000 ounces Au Note that the technical and scientific information disclosed from neighboring properties does not apply to any other properties of the area.
4 Chalice Gold Mines Limited and Northern Superior Resources Inc. Technical Report on the Croteau Est Gold Project, Québec, September 2015, Prepared in accordance with NI 43-101 by Optiro Pty Ltd (“Optiro”) to Chalice Gold Mines Limited and Northern Superior.Croteau hosts an inferred mineral resource of 11.6 Mt at 1.7 g/t Au for 640,000 ounces Au. Note that the technical and scientific information disclosed from neighboring properties does not apply to any other properties of the area.
CAMBRIDGE, MA / ACCESS Newswire / July 11, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, August 1, 2025 to report its second quarter 2025 financial results, and provide a corporate update.
A live webcast of the call will be available under “Events and Presentations” in the Investors section of the Moderna website.
The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for one year following the call.
About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Media Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations 617-209-5834 Lavina.Talukdar@modernatx.com
Wright at Home Roofing & Exteriors is celebrating a big milestone this year—20 years of accreditation with the Better Business Bureau (BBB). This achievement highlights the company’s long-term dedication to maintaining trust and excellent service in the Minneapolis area. As a local Minneapolis contractor, Wright at Home Roofing & Exteriors has consistently put quality and customer satisfaction first for the past 20 years.
The company started with a clear mission: to offer high-quality roofing and exterior solutions. With the BBB accreditation, Wright at Home Roofing & Exteriors gained a platform to support its commitment to ethical business practices and customer-focused services. The company has become a trusted home siding contractor, earning respect and loyalty from the community. You can learn more about their range of services including roofing, siding, and window installations on their website, Wright at Home Roofing & Exteriors.
Wright at Home Roofing & Exteriors’ commitment to Minneapolis is evident in its adherence to BBB’s standards. This accreditation has given them a framework for top-notch service and integrity, which has been key to their long-standing success. They focus on clear communication and reliable services, making them a popular choice among roofing contractors Minneapolis.
The CEO of Wright at Home Roofing & Exteriors, Addison Kaasa, said, “Reaching 20 years with BBB accreditation marks an important achievement for us. It represents our commitment to maintaining the standards our clients expect and highlights our dedication to the community. Our clients’ trust is at the heart of everything we do, and this recognition motivates us to keep providing excellent services.”
Over the last two decades, Wright at Home Roofing & Exteriors has expanded its range of services to meet various home improvement needs. As leading roofing contractors Minneapolis, they now offer thorough inspections, maintenance services, and energy-efficient installations. The company aims to make sure its work supports environmental sustainability and efficiency.
Being accredited with the BBB for 20 years means more than just having a badge. For Wright at Home Roofing & Exteriors, it’s about a continued promise to keep the trust that Minneapolis residents have in them. They view this milestone as a moment to celebrate and as a reminder of their ongoing duty to effective, ethical practices.
“Our 20-year milestone with BBB accreditation speaks volumes about our unwavering dedication to quality and trust,” added a company representative. “This journey wouldn’t have been possible without the support of our clients and the exceptional team we have on board. We look forward to continuing this path with the same integrity and passion.”
Wright at Home Roofing & Exteriors’ reputation as a dependable local Minneapolis contractor goes beyond just roofing and siding services. The company often combines practical skills with community values, a key approach in their work. This milestone reflects the company’s focus on community and its intent to keep adapting to clients’ changing needs. Their storm damage repair services, for instance, are tailored to fit the specific needs of the Minnesota climate, and are supported by a deep understanding of the insurance process.
As they celebrate 20 years of BBB accreditation, Wright at Home Roofing & Exteriors continues to offer innovative solutions while staying true to the principles that have led to their success. Their commitment to building strong community connections and delivering outstanding services forms the foundation for future growth. As a respected name in the industry, Wright at Home Roofing & Exteriors looks forward to serving the Minneapolis community with the same dedication and standards that have been their hallmark over the past two decades. More details on their services and contact information can be found on their website.
About Wright at Home Roofing & Exteriors
Wright at Home Roofing & Exteriors is a second-generation, family-owned roofing and exterior company based in Minneapolis, MN. Since 2005, the company has been committed to doing things The Wright Way—offering transparent quotes, expert craftsmanship, and peace of mind for Minnesota homeowners.
Chehardy Sherman Williams, one of the largest full-service law firms in the Greater New Orleans area, continues to drive meaningful conversations in the healthcare legal space with Health Law Talk, its ongoing podcast series. Hosted by attorneys Rory Bellina, Conrad Meyer, and George Mueller, the podcast offers a practical, informed look at the legal, regulatory, and policy issues that healthcare professionals face today.
Produced at the firm’s Health Law Talk studio, the podcast provides a unique platform where attorneys and subject matter experts weigh in on the most pressing legal topics impacting the healthcare industry. Each episode is designed to be accessible, informative, and relevant, to equip healthcare providers, administrators, and stakeholders with a deeper understanding of how the law intersects with medicine and public policy. Whether the focus is national legislation or Louisiana-specific updates, the Health Law Talk podcast is consistently rooted in real-world legal insight backed by the firm’s extensive experience in the healthcare sector.
The podcast covers a wide range of topics. In a recent episode, Bellina and Meyer broke down some of the year’s most significant healthcare fraud and abuse cases, analyzing how those decisions shape compliance standards. Another episode tackled Louisiana’s therapeutic cannabis program, examining the evolution of the state’s cornerstone medical marijuana statutes and what refinements may come in 2025. Other recent discussions have addressed the extension of federal telehealth flexibilities through September 2025, the growing influence of private equity in healthcare acquisitions, and how physician non-compete clauses are being reshaped by Louisiana’s 2024 Senate Bill 185.
Episodes often feature interviews with industry professionals and legislators, providing a well-rounded perspective on legal issues affecting the healthcare ecosystem. Guests have included Joe Aguilar of HMS Valuation Partners, who spoke on the nuances of healthcare valuation; pediatric orthopedist and attorney Dr. Davida Packer, who shared insights on moral injury in healthcare; and State Representative Thomas Pressly, who joined Maria Bowen from the Louisiana State Medical Society to discuss legislative advocacy and medical policy reform.
While the podcast is a public educational service, Chehardy Sherman Williams notes that the content does not constitute legal advice and should not be interpreted as establishing an attorney-client relationship. The views expressed by guests are their own and do not imply firm endorsement.
Since 1989, Chehardy Sherman Williams has offered legal representation to a broad spectrum of healthcare clients, including physicians, group practices, specialty hospitals, ambulatory surgery centers, imaging facilities, laboratories, and pharmacies. The firm’s healthcare law team provides legal guidance on regulatory compliance, fraud and abuse matters, HIPAA issues, employee and payor contracts, Medicare and Medicaid concerns, insurance reimbursement disputes, and more. With deep knowledge of federal and state-level laws, the firm helps clients navigate a rapidly changing and highly regulated industry.
“Health Law Talk was born out of a simple idea: that complex healthcare issues deserve clear, practical conversations,” said Conrad Meyer. “We’re not just breaking down regulations—we’re opening the door to understanding how the law truly affects the people delivering and receiving care every day.”
“Our goal with Health Law Talk is to give healthcare professionals a space where they can stay ahead of the legal curve—without getting lost in the jargon,” said Rory Bellina. “It’s about making complex policy relatable and offering real context for real-world decisions.”
Episodes of Health Law Talk are available to stream on the firm’s website and major podcast platforms, including Spotify and Apple Podcasts. New episodes are released regularly and reflect the firm’s ongoing commitment to informing and empowering the healthcare community.
For more information about Chehardy Sherman Williams’ work in healthcare law, visit https://chehardy.com, call (504) 833-5600, or stop by:
1 Galleria Blvd Ste 1100
Metairie, LA. 70001
About Chehardy Sherman Williams
Chehardy Sherman Williams is a full-service law firm serving clients across Southeastern Louisiana. With offices in New Orleans, Metairie, and Hammond, the firm offers legal counsel in 10 practice areas, including healthcare law, estate planning, business law, personal injury, family law, real estate, and more. Known for its collaborative approach and unwavering client focus, Chehardy Sherman Williams delivers legal solutions with integrity, insight, and experience.
New Voice AI Assistant Gives Roofing Contractors a Competitive Edge in Storm-Damage Sales
SCOTTSDALE, AZ / ACCESS Newswire / July 10, 2025 / Roofing contractors in storm-affected regions are losing up to 30% of potential jobs due to missed calls and delayed follow-ups, according to industry data. To address this costly gap, Scottsdale-based Convert Peak has launched Phonetix A.I., an advanced voice-powered assistant designed to automate lead response, qualification, and scheduling for roofing businesses.
With homeowners demanding near-instantaneous responses, manual follow-ups, sticky notes, and unanswered voicemails can no longer keep up with homeowner expectations. Phonetix A.I. leverages conversational voice AI and SMS workflows to engage leads immediately, ensuring no opportunity is left on the table.
“Speed-to-lead isn’t just a buzzword-it’s the difference between winning and losing jobs in residential construction,” said DeShawn Tavilla, founder of Convert Peak. “Phonetix A.I. empowers roofing contractors to respond faster than ever, reclaiming lost opportunities and streamlining operations without adding overhead.”
Key Features of Phonetix A.I.:
Instant Voice Response: Answers inbound calls 24/7, even outside business hours.
Smart Lead Qualification: Captures critical details like address, insurance status, and damage type.
Automated Scheduling: Matches homeowner availability and books inspections seamlessly.
CRM Integration: Updates records in real-time and notifies sales teams of booked jobs.
Proven Results: Early adopters of Phonetix A.I. have reported significant improvements, including:
A 25% increase in appointment bookings without additional staff.
A reduction in unqualified leads and unnecessary callbacks.
Faster lead qualification, particularly for storm restoration and insurance-based jobs.
Why It Matters: A recent B2B Marketing Trends report revealed that 40% of local trades businesses are losing revenue due to slow response systems. Phonetix A.I. addresses this challenge head-on, providing roofing contractors with the tools they need to stay competitive in a fast-paced market.
About Phonetix A.I.: Phonetix A.I. joins Convert Peak’s growing suite of sales automation tools, offering voice and SMS workflows, conversational AI, and CRM integration tailored to the unique needs of roofing, construction, and home service businesses.
About Convert Peak: Convert Peak is a performance optimization agency dedicated to helping home service companies nationwide maximize their revenue potential. Specializing in high-converting ad funnels, AI-driven customer engagement, and lead recovery systems, Convert Peak transforms inquiries into booked revenue at scale. Learn more at https://convertpeak.com.
NEW YORK, NY and AUSTIN, TX / ACCESS Newswire / July 10, 2025 / Terra Innovatum Srl (“Terra Innovatum,” or the “Company”), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (Nasdaq:GSRT), a publicly traded special purpose acquisition company, today announcedthat Alessandro Petruzzi, Co-Founder and CEO of Terra Innovatum, Giordano Morichi, Partner, Chief Business Development Officer & Investor Relations of Terra Innovatum, and Anantha Ramamurti, President, Chief Financial Officer and Director of GSRT will participate in a fireside chat at H.C. Wainwright’s Powering the Future: Advancing Innovation Through Nuclear virtual conference.
The virtual fireside chat will take place on Tuesday, July 15, 2025, at 9:30 am ET. A live and archived webcast of the presentation will be accessible on the investors section of Terra Innovatum’s website at https://www.terrainnovatum.com/investors.
Following the fireside chat, management will be available for virtual one-on-one investor meetings. To schedule a meeting, please reach out to an H.C. Wainwright representative or TerraIR@allianceadvisors.com.
ABOUT TERRA INNOVATUM & SOLOTM
Terra Innovatum’s mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 MWe at a time.
Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.
It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.
SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.
Nicholas Hresko-Staab Vice President Investor & Media Relations Alliance Advisors IR E: TerraIR@allianceadvisors.com
IMPORTANT INFORMATION FOR SHAREHOLDERS
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.
In connection with the business combination, a Dutch public limited liability company (“Pubco”), GSR III Acquisition Corp. (“GSRT”) and Terra Innovatum s.r.l. (“Terra Innovatum” and, together with GSR III and Pubco, the “Registrant Parties”) have filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus of Pubco relating to the offer of securities to be issued in connection with the business combination, and a preliminary proxy statement of GSRT to be distributed to holders of GSRT’s ordinary shares in connection with GSRT’s solicitation of proxies for a vote by GSRT’s shareholders with respect to the Business Combination and other matters described in the Registration Statement. The Registrant Parties also plan to file other documents with the SEC regarding the business combination. After the Registration Statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to the shareholders of GSRT. INVESTORS OF THE REGISTRANT PARTIES ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS RELATING TO THE BUSINESS COMBINATION THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.
Investors will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about the Registrant Parties once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. In addition, the documents filed by GSRT may be obtained free of charge by written request to GSRT at 5900 Balcones Drive, Suite 100, Austin TX 78731.
PARTICIPANTS IN THE SOLICITATION
Each of the Registrant Parties, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of GSRT is set forth in GSRT’s filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their direct and indirect interests will be set forth in the Registration Statement (and will be included in the proxy statement/prospectus) and other relevant documents when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.
FORWARD LOOKING STATEMENTS
The statements contained in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on GSRT and the other Registrant Parties. There can be no assurance that future developments affecting GSRT and the other Registrant Parties will be those that we have anticipated. These forward-looking statements speak only as of the date this press release is delivered and involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against GSRT, any of the Registrant Parties, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of GSRT or the SEC’s declaration of the effectiveness of the Registration Statement (which will include the proxy statement/prospectus contained therein) to be filed by the Registrant Parties or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability of Pubco to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Terra Innovatum as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination, including the reorganization described in the business combination agreement; (9) changes in applicable laws or regulations; (10) the possibility that the Registrant Parties or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the amount of redemption requests made by GSRT shareholders and (12) other risk factors described herein as well as the risk factors and uncertainties described in the Form S-4 and GSRT’s other filings with the SEC, as well as any further risks and uncertainties to be contained in the proxy statement/prospectus filed after the date hereof. In addition, there may be additional risks that neither GSRT nor any of the other Registrant Parties presently know, or that GSRT or the other Registrant Parties currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward- looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.
None of GSRT, the other Registrant Parties, or any of their respective affiliates, officers, employees or agents, makes any representation or warranty, either express or implied, in relation to the fairness, reasonableness, adequacy, accuracy, completeness or reliability of the information, statements or opinions, whichever their source, contained in this press release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. GSRT, the other Registrant Parties and their respective affiliates, officers, employees and agents further expressly disclaim any and all liability relating to or resulting from the use of this press release and any errors therein or omissions therefrom. Further, the information contained herein is preliminary, is provided for discussion purposes only, is only a summary of key information, is not complete and is subject to change without notice.
In addition, the information contained in this press release is provided as of the date hereof and may change, and neither GSRT nor the other Registrant Parties undertakes any obligation to update or revise any forward- looking statements, whether as a result of new information, inaccuracies, future events or otherwise, except as may be required under applicable securities laws.
MCLEAN, VA / ACCESS Newswire / July 10, 2025 / Gladstone Commercial Corporation (Nasdaq:GOOD) (the “Company”) announced today that its board of directors declared cash distributions for the months of July, August and September 2025 and also announced its plan to report earnings for the second quarter ended June 30, 2025.
Cash Distributions:
Common Stock: $0.10 cash distribution per common share for each of July, August and September 2025, payable per Table 1 below. The Company has paid 246 consecutive monthly cash distributions on its common stock. Prior to paying distributions on a monthly basis, the Company paid five consecutive quarterly cash distributions.
Table 1: Summary of common stock cash distributions:
Record Date
Payment Date
Cash Distribution
July 21
July 31
$0.10
August 20
August 29
$0.10
September 22
September 30
$0.10
Total for the Quarter:
$0.30
Senior Common Stock: $0.0875 cash distribution per share of the Company’s senior common stock (“Senior Common”) for each of July, August and September 2025, payable per Table 2 below. The Company has paid 183 consecutive monthly cash distributions on its Senior Common.
Table 2: Summary of Senior Common cash distributions:
Payable to Holders of Record During the Month of:
Payment Date
Amount
July
August 4
$0.0875
August
September 5
$0.0875
September
October 3
$0.0875
Total for the Quarter:
$0.2625
Series E Preferred Stock: $0.138021 cash distribution per share of the Company’s 6.625% Series E Preferred Stock (“Series E Preferred Stock”) for each of July, August and September 2025, payable per Table 3 below. The Series E Preferred Stock trades on Nasdaq under the symbol “GOODN.”
Table 3: Summary of Series E Preferred Stock cash distributions:
Record Date
Payment Date
Cash Distribution
July 21
July 31
$0.138021
August 20
August 29
$0.138021
September 22
September 30
$0.138021
Total for the Quarter:
$0.414063
Series F Preferred Stock: $0.125 cash distribution per share of the Company’s 6.00% Series F Preferred Stock (“Series F Preferred Stock”) for each of July, August and September 2025, payable per Table 4 below. The Series F Preferred Stock is not listed on a national securities exchange.
Table 4: Summary of Series F Preferred Stock cash distributions:
Record Date
Payment Date
Cash Distribution
July 25
August 4
$0.125
August 27
September 5
$0.125
September 24
October 3
$0.125
Total for the Quarter:
$0.375
The Company offers a dividend reinvestment plan (the “DRIP”) to its common stockholders and Series F Preferred stockholders. For more information regarding the DRIP, please visit www.gladstonecommercial.com.
Series G Preferred Stock: $0.125 cash distribution per share of the Company’s 6.00% Series G Preferred Stock (“Series G Preferred Stock”) for each of July, August and September 2025, payable per Table 5 below. The Series G Preferred Stock trades on Nasdaq under the symbol “GOODO.”
Table 5: Summary of Series G Preferred Stock cash distributions:
Record Date
Payment Date
Cash Distribution
July 21
July 31
$0.125
August 20
August 29
$0.125
September 22
September 30
$0.125
Total for the Quarter:
$0.375
Earnings Announcement:
The Company also announced today that it plans to report earnings for the second quarter ended June 30, 2025, after the stock market closes on Wednesday, August 6, 2025. The Company will hold a conference call Thursday, August 7, 2025 at 8:30 a.m. ET to discuss its earnings results. Please call (877) 407-9045 to enter the conference call. An operator will monitor the call and set a queue for questions.
A conference call replay will be available after the call and will be accessible through August 14, 2025. To hear the replay, please dial (877) 660-6853 and use playback conference number 13754186.
The live audio broadcast of the Company’s conference call will be available online at www.gladstonecommercial.com.
If you have questions prior to or following the earnings release you may e-mail them to info@gladstonecompanies.com.
Gladstone Commercial Corporation is a real estate investment trust (“REIT”) focused on acquiring, owning and operating net leased industrial and office properties across the United States. As of March 31, 2025, Gladstone Commercial’s real estate portfolio consisted of 141 properties located in 27 states, totaling approximately 17.3 million square feet. Additional information can be found at www.gladstonecommercial.com.